US Patent Issued to JAZZ PHARMACEUTICALS RESEARCH UK on July 8 for "Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease" (Spanish, British Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,350,253, issued on July 8, was assigned to JAZZ PHARMACEUTICALS RESEARCH UK Ltd. (Sittingbourne, Great Britain).

"Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease" was invented by Benjamin Whalley (Cambridge, Great Britain), Javier Fernandez-Ruiz (Madrid) and Rosario Moratalla Villalba (Madrid).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternativel...